Novartis AG
NOVN.SW - SWISS EXCHANGE
Industry: Pharmaceuticals
Market Cap: 173.4 B
IPO Date: May 7, 2001
Country: CH
Currency: USD
Shares Outstanding: 2.1 B
Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating
5/7/2025
Uncertainty around ELEVIDYS sales impact Sarepta Therapeutics, Inc. Click here to find out why I downgraded SRPT stock to a Hold.
Source: SeekingAlpha
The Play On Legend Biotech
5/3/2025
Legend Biotech faces a 60% stock drop amid safety, supply issues, and competition for its CAR-T therapy, Carvykti. See here for an analysis of LEGN stock.
Source: SeekingAlpha
Novartis to buy Regulus Therapeutics for as much as $1.7 billion
5/2/2025
Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.
Source: Yahoo
Biotech Alert: Searches spiking for these stocks today
5/1/2025
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 6,307% surge in interest CG Oncology (CGON), 3,377% surge in interest Chemomab Therapeutics (CMMB), 3,029% surge in interest BioCardia (BCDA), 1,244% surge in interest Senti Biosciences (SNTI), 1,175% surge in interest Tevogen Bio Holdings (TVGN), 332% surge in interest Regulus Therapeutics (RGLS), 223% surge in interest Spr
Source: Yahoo
Novartis to strengthen renal disease portfolio with Regulus
5/1/2025
Total consideration for the acquisition, including the CVR, could reach $1.7bn.
Source: Yahoo
Franklin Global Equity Fund Q1 2025 Commentary
4/30/2025
Stock selection was mixed at the region and sector level and modestly detracted overall. Click here to read the full commentary.
Source: SeekingAlpha
Franklin Mutual International Value Fund Q1 2025 Commentary
4/30/2025
The Franklin Mutual International Value Fund outperformed its benchmark, the MSCI EAFE Value Index, for Q1 2025. Click here to read the full commentary.
Source: SeekingAlpha
Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements
4/30/2025
Regulus Therapeutics will be acquired by Novartis AG for $7 per share in cash. Click here for more information on RGLS acquisition.
Source: SeekingAlpha
Why Novartis (NVS) is a Top Value Stock for the Long-Term
4/30/2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Source: Yahoo
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
4/30/2025
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Source: Yahoo
Novartis to acquire Regulus in deal for kidney disease drug
4/30/2025
The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance microRNA technology.
Source: Yahoo
Novartis to Acquire Regulus in $1.7 Billion Deal
4/30/2025
With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.
Source: Yahoo
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal
4/30/2025
(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the deal terms, Novartis will pay $7 per share in cash upfront, or about $800 million, and another $7 per share to Regulus shareholders if the lead drug candidate, farabursen, gets regulatory approval, the California-based biotech said on Wednesday. The deal, expected to bolster Novartis' lineup of kidney disease drugs in development, will also give the company access to Regulus' proprietary platform to develop treatments targeting a type of genetic material called microRNAs.
Source: Yahoo
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
4/30/2025
Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal diseaseLead asset for ADPKD, farabursen, is a novel, next-generation oligonucleotide targeting miR-17 that recently completed a Phase 1b multiple-ascending dose clinical trial Transaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a future regulatory milestone;
Source: Yahoo
Novartis: Guidance 2025 Raised To Top End Of Prior Range - Buy Confirmed
4/30/2025
Source: SeekingAlpha
Novartis AG (NVS) Q1 2025 Earnings Call Highlights: Impressive Growth and Strategic Advancements
4/30/2025
Novartis AG (NVS) reports robust sales and income growth, while navigating challenges and enhancing its product pipeline.
Source: Yahoo
Novartis Scores A Beat-And-Raise Quarter — And Shares Make A Break For A Buy Point
4/29/2025
Novartis stock made a break for a buy point Tuesday after the drugmaker beat first-quarter expectations and raised its full-year outlook.
Source: Yahoo
Novartis AG (NVS) Q1 2025 Earnings Call Transcript
4/29/2025
Novartis AG (NYSE:NVS) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ETCompany ParticipantsSloan Simpson - Head of Investor RelationsVas...
Source: SeekingAlpha